The papillomavirus E1 helicase, with the help of E2, assembles at the viral origin into a double hexamer that orchestrates replication of the viral genome. The N-terminal region (NTR) of E1 is essential for DNA replication in vivo but dispensable in vitro, suggesting that it has a regulatory function. By deletion analysis, we identified a conserved region of the E1 NTR needed for efficient replication of viral DNA. This region is predicted to form an amphipathic ␣-helix (AH) and shows sequence similarity to portions of the p53 and herpes simplex virus (HSV) VP16 transactivation domains known as transactivation domain 2 (TAD2) and VP16C, which fold into ␣-helices upon binding their target proteins, including the Tfb1/p62 (Saccharomyces cerevisiae/human) subunit of general transcription factor TFIIH. By nuclear magnetic resonance (NMR) spectroscopy and isothermal titration calorimetry (ITC), we found that a peptide spanning the E1 AH binds Tfb1 on the same surface as TAD2/VP16C and with a comparable affinity, suggesting that it does bind as an ␣-helix. Furthermore, the E1 NTRs from several human papillomavirus (HPV) types could activate transcription in yeast, and to a lesser extent in mammalian cells, when fused to a heterologous DNA-binding domain. Mutation of the three conserved hydrophobic residues in the E1 AH, analogous to those in TAD2/VP16C that directly contact their target proteins, decreased transactivation activity and, importantly, also reduced by 50% the ability of E1 to support transient replication of DNA in C33A cells, at a step following assembly of the E1-E2-ori preinitiation complex. These results demonstrate the existence of a conserved TAD2/VP16C-like AH in E1 that is required for efficient replication of viral DNA.
Human papillomaviruses (HPVs) are small DNA tumor viruses that infect stratified epithelium from skin or mucosa. Among the 150 or more HPV types identified so far, there are at least 25 that infect the anogenital tract. Those types are classified either as low risk if they cause only benign lesions, such as warts, or as high risk if they can lead to the development of cancer. Infection by a high-risk HPV type is a necessary cause for the development of cervical cancer, the second most common malignancy among women in the world (42) . HPVs establish their double-stranded DNA genomes as episomes in the nuclei of undifferentiated keratinocytes from the basal layer of the epithelium and rely on the differentiation program that these cells undergo to complete their viral life cycle (reviewed in reference 14) . Replication of the viral genome is accomplished by the E1 and E2 proteins in conjunction with the host cell DNA replication machinery. E1 is a helicase that is recruited by E2 to the viral origin of replication (ori). E1 assembles on the ori as a double hexamer that unwinds DNA ahead of the bidirectional replication fork and also recruits DNA polymerase ␣-primase (DNA Pol ␣), replication protein A (RPA), and other host replication factors to promote viral DNA replication (reviewed in reference 49).
The E1 protein can be divided into three functional segments ( Fig. 1A) : the N-terminal regulatory region (NTR), the central origin-binding domain (OBD) , and the C-terminal helicase domain. The helicase domain contains sequences important for oligomerization of the protein and for interaction with E2 and DNA Pol ␣, and as its name indicates, it has helicase/ ATPase activities (36, 53, 58) . The OBD and C-terminal helicase domain are both necessary and sufficient to catalyze viral DNA replication in vitro, in a cell-free system (2) . Although the NTR of E1 is dispensable for DNA replication in vitro, it is essential in vivo, suggesting that it has a regulatory function (2, 51) . The NTR was previously shown to contain a bipartite nuclear localization sequence (NLS), a nuclear export sequence (NES), a cyclin-binding motif (CBM), and Cdk2 phosphorylation sites important for the accumulation of E1 in the nucleus, where viral DNA replication takes place. Functioning together, these motifs regulate the nucleocytoplasmic shuttling of E1 (11, 18, 32, 63) . These motifs are all contained within a short region, located between residues 83 and 125 of E1 (for HPV type 31 [HPV31]; Fig. 1A ), which we refer to as the "shuttling module." We previously reported that the NTR also contains a binding site for the cellular protein p80, within its first 40 amino acids (aa) (Fig. 1A) . Mutations in this site that abrogate p80 binding severely reduced the ability of E1 to support transient replication of DNA and abolished its ability to maintain the viral genome in immortalized keratinocytes (8, 19) . Finally, the E1 NTR also contains two overlapping caspase 3/caspase 7 cleavage sites (DxxDxxD), located between the p80-binding region and the shuttling module (Fig. 1A) , whose cleavage is required for viral genome amplification in differentiated keratinocytes (37, 38) .
A previous study by Demeret et al. (10) suggested that HPV18 E1 can function as a transcriptional transactivator when interacting with E2 or when fused directly to the DNAbinding domain (DBD) of E2. Similarly, we and others observed in the course of yeast two-hybrid studies that E1 can activate transcription when fused to the heterologous DNAbinding domain of Gal4 or LexA. This ability of E1 to activate transcription in Saccharomyces cerevisiae could be mapped to the NTR, more precisely to sequences located between amino acids 1 and 190 of HPV16 E1 and amino acids 1 and 72 of HPV11 E1 (54, 61) . However, the precise domain of E1 responsible for this "transactivation activity" has not been identified, and as a result, its function in DNA replication has never been tested.
Here we performed a systematic deletion analysis of the HPV31 E1 NTR and found that residues 40 to 50, located between the p80-binding site and shuttling module, are essential for efficient replication of DNA. This region of E1 is predicted to form an amphipathic ␣-helix (AH) and shows sequence similarity to the transactivation domain 2 of the tumor suppressor p53 (p53 TAD2) and to the related transactivation subdomain C of herpes simplex virus protein 16 (HSV VP16C), which both fold into an AH upon binding to their target proteins. These TADs are characterized by their acidic nature and the presence of three hydrophobic residues that make direct contact with their target proteins, such as the Tfb1/p62 (yeast/human) subunit of general transcription factor TFIIH (transcription factor IIH) (12, 30, 59) . Accordingly, we determined by nuclear magnetic resonance (NMR) spectroscopy and isothermal titration calorimetry (ITC) that a peptide spanning the E1 AH binds to Tfb1 with a comparable affinity and through the same binding surface as p53 TAD2 and VP16C. Consistent with these results, we found that the E1 NTRs from several HPV types activate transcription in yeast and, to a lesser extent, in mammalian cells when fused to a heterologous DNA-binding domain. Furthermore, this activity was reduced by mutation of the three hydrophobic residues in E1 that correspond to those in p53 TAD2 and VP16C which mediate their interaction with target proteins, including Tfb1/ p62. Importantly, we show that mutation of these three key residues in E1 also reduce by half its ability to support transient DNA replication in C33A cervical carcinoma cells, at a step subsequent to the assembly of the E1-E2 complex at the origin. These results highlight the importance of this conserved TAD2/VP16C-like AH in E1 for viral DNA replication.
MATERIALS AND METHODS
Plasmid constructions and mutagenesis. Plasmid pSH18-34 (Invitrogen) expressing LacZ under the control of eight LexA operators was used as the reporter gene for the ␤-galactosidase assays in yeast. LexA DNA-binding domain (DBD) fusion proteins were expressed from pEG202-NLS-MCS (MCS stands for multicloning site), a modified version of pEG202 (Origene) in which a sequence containing genes encoding the simian virus 40 (SV40) nuclear localization sequence (NLS) and restriction sites for NcoI, NotI, SacII, and BamHI has been inserted between the EcoRI and XhoI sites. The sequence containing genes encoding the sequence from amino acids (aa) 1 to 83 of human papillomavirus type 31 (HPV31) E1 was inserted between the NcoI and BamHI restriction sites of pEG202-NLS-MCS. Analogous constructs coding for HPV6 E1(1-80) (truncated E1 protein from HPV6 that contains amino acids 1 to 80), HPV11 E1(1-80), HPV16 E1(1-84), and HPV18 E1(1-83) were also produced. Plasmids coding for Flag-tagged E1 (Flag-E1) and truncated derivatives were constructed by inserting the codon-optimized sequence of HPV31 E1 between the BamHI and EcoRI restriction sites of pCMV-3Tag-1a (Stratagene) (CMV stands for cytomegalovirus). The plasmid used to express enhanced yellow fluorescent protein (EYFP)-tagged HPV31 E1 (EYFP-HPV31 E1) was described previously (8) . For purification of HPV31 E1(2-332) in bacteria, glutathione S-transferase (GST) fusion proteins were expressed from plasmid pGEX-4T-1 in which the E1 coding sequence was inserted between the EcoRI and SalI restriction sites. Plasmid pG5luc (Promega), containing 5 Gal4-binding sites upstream of the firefly luciferase gene, was used as the reporter gene for the transactivation assays in mammalian cells. Gal4 DBD fusion proteins were expressed from the pM vector (Clontech). Sequences from p53(1-73) (truncated p53 with amino acids 1 to 73), p53 TAD2(40-73) (truncated p53 with amino acids 40 to 73 of TAD2), HPV6 E1(1-80), HPV11 E1(1-80), HPV16 E1(1-84), HPV18 E1(1-83), and HPV31 E1(1-83) were inserted in pM between the BamHI and EcoRI sites and the codon-optimized sequence coding for HPV31 E2 TAD (aa 2 to 208) was inserted between the BamHI and HindIII sites. Site-directed mutagenesis was performed using the QuikChange mutagenesis kit (Stratagene). All DNA constructs were verified by sequencing. Further details on their constructions will be provided upon request.
Transactivation assays in Saccharomyces cerevisiae. Saccharomyces cerevisiae strain EGY48 (MATa leu2-3,112 his3-11,15 trp1-1 ura3-1 6xLexAop-LEU2 ) or BY4741 (MATa his3-1 leu2-0 met15-0 ura3-0) and its derivatives carrying a deletion of ADA1, GCN5, or SPT7 were transformed with the LexA operatorlacZ fusion plasmid pSH18-34 and a vector encoding the indicated LexA DBD fusion proteins. For each transformation, ␤-galactosidase activity was determined from three independent samples, and average values are reported with standard deviations. To measure ␤-galactosidase activity, the transformed cells were pregrown overnight in synthetic defined (SD) liquid medium lacking uracil and histidine and then used to inoculate new cultures in fresh medium. These cultures were grown at 30°C until they reached an optical density at 600 nm (OD 600 ) of approximately 0.6. The cells were then harvested, washed, and permeabilized by three cycles of freezing and thawing. ␤-Galactosidase activity was measured spectrophotometrically (at 578 nm) with the substrate chlorophenol red-␤-D-galactopyranoside (CPRG) (Roche) as previously described (7a). Enzymatic activity was calculated by the following equation: Miller units ϭ (1,000 ϫ OD 578 )/(elapsed minutes ϫ V ϫ OD 600 ) where V ϭ 0.1 ϫ concentration factor of the culture. One Miller unit is defined as the amount of ␤-galactosidase that hydrolyzes 1 mol of CPRG to chlorophenol red and D-galactose per minute per cell.
Transactivation assays in mammalian cells. C33A cells were plated in white flat-bottom 96-well plates at a density of 25,000 cells/well and transfected 20 h later. For each well, 100 ng of pG5luc was transfected along with 25, 50, and 100 ng of vector expressing the indicated Gal4 DBD fusion protein (see Fig. 5 ) or with pM as a control, and 0.5 ng of pRL as a Renilla luciferase internal control. The culture medium was changed 4 h after transfection. Firefly and Renilla luciferase activities were measured 48 h posttransfection using the Dual-Glo luciferase assay system (Promega).
Western blotting and antibodies. Proteins fused to enhanced yellow fluorescent protein (EYFP) were detected using a mixture of two mouse monoclonal antibodies against green fluorescent protein (GFP), purchased from Roche (catalog no. 11814460001). Proteins fused to the LexA or Gal4 DBD were detected using mouse monoclonal antibodies from Santa Cruz Biotechnology (catalog no. sc-7544 or sc-510, respectively). Proteins fused to the triple-Flag epitope were detected using the mouse monoclonal antibody Flag M2 from Sigma-Aldrich (catalog no. F1804). Human ␤-tubulin, yeast ␤-actin, and human caspase 3 were detected using a mouse monoclonal antibody from Sigma-Aldrich (catalog no. T0426), a mouse monoclonal antibody from Abcam (catalog no. ab8224), and a rabbit polyclonal antibody from Cell Signaling Technology (catalog no. 9662), respectively. The rabbit antiserum against the C-terminal domain of p80 was kindly provided by Jae U. Jung (University of Southern California). For Western blot analysis, proteins were transferred onto polyvinylidene difluoride membranes and detected using horseradish peroxidase-conjugated secondary antibodies from GE Healthcare, either sheep anti-mouse IgG (catalog no. NA931) or donkey anti-rabbit IgG (catalog no. NA934V), and an enhanced chemiluminescence detection kit (GE Healthcare).
NMR spectroscopy studies. A synthetic peptide containing amino acids 44 to 63 of HPV11 E1 [HPV11 E1 (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) (63) ] was purchased from the Sheldon Biotechnology Centre (McGill University, Montréal, Canada) and purified to homogeneity by reverse-phase high-performance liquid chromatography (HPLC) using a C 4 column (Vydac). The amino acid sequence of the peptide is EEEVEDSGY DMVDFIDDRG. Tfb1 (amino acids 1 to 115) was expressed as a GST fusion protein and purified as previously described (13 Cell culture and transfections. C33A cervical carcinoma cells were grown in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% bovine serum (FBS), 0.5 IU/ml of penicillin, 50 g/ml streptomycin, and 2 mM L-glutamine. Transfections were performed using the Lipofectamine 2000 reagent according to the manufacturer's recommendations (Invitrogen).
Luciferase DNA replication assay. The luciferase DNA replication assay was performed essentially as described previously, but using EYFP-tagged E1 (EYFP-E1) instead of Flag-tagged E1, unless indicated otherwise (19) . Briefly, C33A cells were plated 20 h before transfection in white flat-bottom 96-well plates at a density of 25,000 cells/well. When different amounts of EYFP-E1 expression plasmid (pEYFP-HPV31 E1) were used, the quantity of plasmid DNA was adjusted to 50 ng with the empty vector (pEYFP-C1; Clontech). For all experiments, 10 ng of a plasmid expressing Flag-tagged E2 (p31E2) and 40 ng of the empty plasmid (pCMV-3Tag-1a; Stratagene), in addition to 2.5 ng of the origin-containing plasmid pFLORI31 (firefly luciferase [Fluc] ) and 0.5 ng of the Renilla luciferase internal control (pRL) were transfected. The culture medium was changed 4 h posttransfection. Firefly and Renilla luciferase activities were measured using the Dual-Glo luciferase assay system (Promega) 72 h posttransfection. Plasmids p31E2, pFLORI31, and pRL were previously described (19) .
Flow cytometry analysis. A total of 8 ϫ 10 5 C33A cells were transfected with 250, 500, 750, and 1,000 ng of the indicated EYFP-HPV31 E1 expression plasmid in duplicate samples. The cells were harvested 24 h later, resuspended in phosphate-buffered saline (PBS) containing 10% FBS, and analyzed by flow cytometry using a FACScan cytometer with the CellQuest Pro software (BD Biosciences). The mean fluorescence intensity per cell was determined for the EYFPpositive cell population.
Confocal fluorescence microscopy. A total of 8 ϫ 10 5 C33A cells were transfected with 1 g of EYFP-HPV31 E1 expression plasmid and grown on coverslips. The cells were fixed 24 h later with 4% formaldehyde, DNA was stained with TO-PRO 3 (Molecular Probes), and coverslips were mounted using Vectashield mounting medium (Vector Laboratories). Images were acquired using an LSM510 confocal laser coupled to an Axiovert 100M inverted scanning microscope (Zeiss, Toronto, Canada) and analyzed using LSM Image Browser version 3.2.0.70 (Zeiss, Toronto, Canada).
Purification of E1 fragments from bacteria. E1 fragments were produced as GST fusion proteins in Escherichia coli BL21(DE3) (Novagen) as previously described (47) . GST-E1 fusion proteins were purified and cleaved with thrombin to remove the GST moiety and further processed as described previously (20) . All protein concentrations were determined by Bradford analysis.
Fluorescence polarization DNA-binding assay. DNA-binding assays were performed as previously described (20) using 10 nM fluorescein-labeled probe and the indicated concentrations of protein (see Fig. 8C ) in the following buffer: 20 mM Tris-HCl (pH 7.6), 50 mM NaCl, 0.01% NP-40, and 1 mM DTT. Fluorescence readings were taken after a 30-min incubation at 4°C using a Wallac 1420 multilabel HTS counter (Victor 3 V) equipped with a 485-nm/535-nm filter set. Background fluorescence from buffer was subtracted, and polarization values (P) were defined as follows: P ϭ (I ԽԽ Ϫ I Ќ )/(I ԽԽ ϩ I Ќ ), where I ԽԽ and I Ќ are the fluorescence intensities recorded in the parallel and perpendicular orientations relative to the excitation polarizer, respectively. Fluorescein-labeled oligonucleotides were purchased from Invitrogen, with the fluorophore attached at the 5Ј end by a six-carbon linker. Duplex DNA probes were prepared by annealing each fluorescein-labeled oligonucleotide to a complementary oligonucleotide at a ratio of 1:1.5 as previously described (20) .
Caspase cleavage assay. A total of 8 ϫ 10 5 C33A cells were transfected in 6-well plates with 1.2 g of vectors expressing EYFP-HPV31 E1. The cells were treated 24 h posttransfection with 2 M staurosporine (Sigma-Aldrich) or 0.2% dimethyl sulfoxide (DMSO) alone as the vehicle for 4 h. The cells were then lysed, and extracts were analyzed by SDS-PAGE and Western blotting using anti-GFP and anti-caspase 3 antibodies.
RESULTS

Deletion analysis of the HPV31 E1 N-terminal region.
The N-terminal region (NTR) of E1 is required for viral DNA replication in vivo but not in vitro, suggesting that it has a regulatory function. The E1 NTR contains a binding site for the cellular protein p80 and a "shuttling module" that mediates the nuclear import and export of E1 (Fig. 1A) (8, 11, 18, 32, 63) . Both domains are separated by a short region containing two overlapping caspase 3/caspase 7 cleavage sites (Fig. 1A ) that are required for the differentiation-dependent amplification of the viral genome (37) . To examine in more detail the role of the E1 NTR in viral DNA replication, we constructed a set of N-terminal deletions in HPV31 E1 at 10-amino-acid intervals (C10, C20, C30, and C40). We also created two deletions that mimic the form of E1 cleaved by caspase 3/caspase 7 at either of the two overlapping caspase sites (C50 and C53). Further truncations into the shuttling module were not created, as those would be expected to affect the replication activity of E1 by preventing its nuclear import. Each E1 truncation was tested using our recently described luciferase-based transient DNA replication assay (19) . This assay is based on a plasmid containing the viral origin of replication (ori) that also carries a firefly luciferase reporter gene in cis of the ori, such that replication of this plasmid by E1 and E2 results in increased expression of firefly luciferase (19) . Each fragment of E1 was tested at three different amounts (1.25, 2.5, and 5 ng of Flag-tagged E1 [Flag-E1] expression plasmid) in duplicate experiments, and luciferase activities were determined 72 h posttransfection. As shown in Fig. 1B , truncation C10 was as active as wild-type E1. In contrast, truncations C20, C30, and C40 reduced viral DNA replication by 50 to 70%. These truncations remove part or all of the p80-binding site (aa 10 to 40) (8). Interestingly, the effects of these truncations are very similar to the effects of specific amino acid substitutions in E1 that prevent p80 binding. Indeed, we previously reported that three 2-amino-acid substitutions in E1 that prevent p80 binding also reduce viral DNA replication by 50 to 70% (8, 19) . Interestingly, the two larger deletions C50 and C53, which mimic the forms of E1 resulting from caspase cleavage at the first or second site, were both inactive (Fig. 1B) , thus indicating that sequences located between amino acids 40 and 50 play an important role in viral DNA replication. For a control, we verified that these E1 truncations were expressed at comparable levels by Western blotting against their triple-Flag epitope and thus that their replication defects were not due to a reduction in protein expression or stability (Fig. 1C) .
The findings that C40 retains some replication activity whereas C50 is completely inactive suggested that the region located between amino acids 40 and 50 plays an important role in viral DNA replication, independently of the p80-binding site (which is completely lacking in C40). Although this region contains the two overlapping caspase 3/caspase 7 cleavage sites, it is unlikely that caspase cleavage of E1 plays a significant role in our assay, since little to no cleavage of E1 is detected in the C33A cells used for the DNA replication assay (37) (see Fig. S1 in the supplemental material). However, to conclusively rule out an effect of caspases in our DNA replication assay, we mutated the three aspartates of the two overlapping (D46xxD49xxD52) caspase cleavage sites and confirmed that the resulting three E1 mutants were as active as the wild-type protein (see Fig. S2 in the supplemental material).
Collectively, the results presented above indicate that residues 40 to 50 of HPV31 E1 contribute to viral DNA replication independently of the p80-binding domain and caspase cleavage sites. As such, they also raise the possibility that residues 40 to 50 of HPV31 E1 encode a previously unrecognized activity required for efficient replication of viral DNA.
Residues 40 to 50 of HPV31 E1 span a predicted amphipathic ␣-helix with sequence similarity to the p53 TAD2 and VP16C transactivation domains. As a first step toward understanding the role of amino acids 40 to 50 of E1 in HPV DNA replication, we analyzed their potential secondary structure in silico. Several bioinformatics analyses of the E1 NTR predicted that amino acids 40 to 50 lie within an intrinsically disordered domain (IDD). Figure 2A shows the predictions obtained with three different protein disorder prediction programs, MetaPrDos (http://prdos.hgc.jp/meta/) (27) and the two GeneSilico programs metadisorder binCons and floatCons (http://iimcb.genesilico.pl/metadisorder/) (29) , which use several individual analyses to make a consensus prediction. Each program provides a score of disorder probability between 0 and 1 for every amino acid of the protein; a region is predicted to be disordered if the scores are higher than 0.5. All three programs suggested a highly unstructured region located between amino acids 27 and 48 of HPV31 E1 ( Fig. 2A) .
A closer examination of the interval of E1 from amino acids 40 to 50 showed that it has sequence similarity to two other and well-characterized IDDs, namely, to the transactivation domains of p53 and VP16 (Fig. 2B) . p53 contains two separable transactivation subdomains in its N terminus, located between residues 1 to 40 (TAD1) and residues 40 to 73 (TAD2) (7, 48).
FIG. 2. The E1 N-terminal region contains a predicted intrinsically disordered region with similarity to the p53 TAD2 and VP16C transactivation domains. (A) Protein disorder and secondary structure predictions for the HPV31 E1 N-terminal region. Graph indicating the disorder probability score for every residue of HPV31 E1(1-83) obtained with three different predictors: MetaPrDos (black line), GeneSilico metadisorder binCons (green line), and GeneSilico metadisorder floatCons (blue line). The secondary structure (ss) prediction for HPV31 E1(1-83) was obtained with the Porter predictor and is indicated below the E1 amino acid (aa) sequence as follows: H, helix; E, strand; C, coil. The p80-binding domain is underlined (p80). The MxxFI motif is boxed. (B) Sequence alignment of part of the E1 N-terminal region from different HPV types together with the transactivation domains of p53 TAD2 and HSV VP16C. The three conserved hydrophobic residues are shown in white letters on a black background. The putative CK2 sites in E1 and the S46 phosphorylation site in p53 are boxed. (C) Structural details of the Tfb1-p53 and Tfb1-VP16 interactions. The surface of Tfb1 is shown in green with the backbone trace of either the p53 TAD2 helix (orange) or the VP16C helix (in red). The side chains of the three hydrophobic residues of p53 and VP16 important for the interaction with Tfb1 are shown.
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The VP16 TAD also contains two similar autonomous subdomains, named VP16N and VP16C (28) . Both the p53 TAD2 and VP16C are largely unstructured in solution but fold into a 9-residue ␣-helix upon binding to their target proteins ( Fig.  2C ) (5, 12, 28, 56) . These TADs contain many acidic residues surrounding three critical hydrophobic residues that make direct contacts with target proteins and that are essential for transactivation activity. Interestingly, these three hydrophobic residues (M47, F50, and I51 for HPV31 E1) are highly conserved among E1 from different HPV types (Fig. 2B , residues on a black background). Furthermore, the short region containing these conserved residues ( 47 MVDFI 51 ; referred herein as the MxxFI motif) has a lower disorder score (around 0.35) and is predicted by different secondary structure programs, including the Porter program (http://distill.ucd.ie/porter/) (44) , to lie within a short ␣-helix (boxed region in Fig. 2A) . Interestingly, the Porter program also predicts helices for the analogous regions of p53 TAD2 and VP16C (data not shown). Finally, the p53 TAD2 also contains a phosphorylation site (S46) that enhances its transactivation activity by increasing its binding to target proteins (6, 12, 41) . A potential CK2 phosphorylation site is present and conserved at a similar position in E1 (T43 for HPV31 E1, Fig. 2B , boxed) but is absent in VP16C. Collectively, the bioinformatics predictions described above suggest that the role of E1 amino acids 40 to 50 in viral DNA replication may involve formation of a short amphipathic ␣-helix (AH) over the MxxFI motif. Importantly, the E1 proteins from other anogenital HPV types are also predicted to contain this short amphipathic ␣-helix within a similar IDD (see Fig. S3 in the supplemental material).
The E1 amphipathic helix is structurally related to p53 TAD2 and HSV VP16C. The TADs of p53 and HSV VP16 have been shown to make direct contacts with several components of the RNA polymerase II transcription machinery. One of our laboratories (J. G. Omichinski) has previously reported that the p53 and VP16 TADs bind with high affinity to the Tfb1/p62 subunit of the yeast/human general transcription factor IIH (TFIIH), a common target of many acidic TADs (12, 13, 30) . In addition, we have determined that both p53 TAD2 and VP16C form 9-residue ␣-helices upon binding to the PH (pleckstrin homology) domain of Tfb1 (amino acids 1 to 115) (12, 30) . The structures of these two complexes have revealed a simple recognition code for the Tfb1/p62 subunit of TFIIH and made it possible to identify putative acidic TADs in other proteins based on sequence alignments. Given that the E1 AH resembles p53 TAD2 and VP16C based on this recognition code for Tfb1/p62 (Fig. 2B ), we were interested in determining whether a peptide corresponding to this region of HPV11 E1 (aa 44 to 63) was in fact capable of interacting with the PH domain of Tfb1.
To determine whether HPV11 E1(44-63) could interact with Tfb1 in a manner similar to p53 TAD2 and VP16C, we performed NMR chemical shift mapping studies. Additions of HPV11 E1 (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) (63) 15 N heteronuclear single-quantum coherence (HSQC) spectra (Fig. 3A) . When mapped onto the NMR solution structure of free Tfb1, the residues displaying significant chemical shift changes (Fig. 3B) clustered on strands ␤5, ␤6, and ␤7 (Fig. 3C) . On the basis of these changes (1-115) . The binding site for the p53 TAD2, as determined by NMR mapping studies (12) , is highlighted in yellow. Strands contacting E1 and p53 are identified on the structure. in chemical shifts, the HPV11 E1(44-63)-binding site on Tfb1 is similar to that of p53 TAD2 (Fig. 3D) . It is also comparable to that of VP16C, because the latter uses the same binding surface as p53 (data not shown). In addition, isothermal titration calorimetry (ITC) analysis demonstrated that HPV11 E1 (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) (63) Fig. 4A ; also see Fig. S4A in the supplemental material). Note that the transactivation activity of each LexA fusion protein used in this study is reported in ␤-galactosidase Miller units in Fig. S4A and S5A in the supplemental material and shown graphically in Fig. 4 as fold activation of the reporter gene, obtained by dividing each ␤-galactosidase value by that obtained with LexA alone (control). The TADs of p53 and VP16 also activate transcription in yeast when tethered to DNA by fusion with a heterologous DNA-binding domain (9, 17) . For comparison with E1, we tested the activity of the two p53 TADs fused to LexA, either individually or in combination. As previously reported, we found that the expression of LexA-p53(1-73), carrying both TAD1 and TAD2, was toxic to yeast cells (Fig. 4B) (17, 26, 40) , a fact that prevented measuring its true transactivation activity. As might be expected from its toxicity, LexA-p53(1-73) was expressed at very low levels (see Fig. S4B in the supplemental material). In contrast, the p53 TAD1 and TAD2 were not toxic when expressed separately as LexA fusions and accumulated at levels similar to those of LexA-HPV31 E1(1-83) (see Fig. S4B in the supplemental material). In ␤-galactosidase assays, the transactivation activities of p53 TAD1 and TAD2 were comparable and about 3-fold higher than that measured for the N-terminal part of HPV31 E1 (Fig. 4A) . Thus, the E1 NTR has a relatively strong transactivation activity in yeast, approaching that of p53 TAD1 and TAD2. Importantly, the combined mutation of the three hydrophobic residues M47, F50, and I51 to alanine (MFI mutation) in the E1 AH severely reduced the transcriptional activity of the NTR. We also tested whether mutation of the putative CK2 site (T43) to either alanine or glutamate (as a phosphomimetic) had any effect on the activity of E1 NTR. Both mutants were able to transactivate the LacZ reporter gene to degrees similar to that of the wild-type protein ( Fig.  4A ; see Fig. S4A in the supplemental material) . Collectively, these results indicate that HPV31 E1 possesses an intrinsic transactivation activity in yeast that is conferred by its AH region but that does not appear to be modulated by phosphorylation of T43.
Next, we investigated whether the E1 proteins from other anogenital HPV types could also activate transcription in yeast when fused to LexA. The E1 N-terminal regions from the two low-risk types HPV6 and HPV11, as well as those from the oncogenic types HPV16 and HPV18, were all able to activate transcription ( Fig. 4A; see Fig. S4A in the supplemental material) and were expressed to comparable levels (see Fig. S4B in the supplemental material). Thus, the E1 proteins from both high-and low-risk HPV types can activate transcription in yeast. The E1 N-terminal regions from HPV6 and -18 displayed the most robust activity, being able to transactivate the reporter gene by 186-and 195-fold, respectively, similar to the levels obtained with p53 TAD2. Importantly, the transcriptional activities of the HPV6, -11, -16, and -18 NTRs were abolished by mutations of the three conserved hydrophobic From these results, we conclude that the ability of the N-terminal region of E1 to activate transcription in yeast is a conserved feature of this viral helicase from both low-and high-risk HPV types. Finally, we also investigated whether the transactivation activity of the E1 NTR in yeast was dependent on some of the same factors as those required for p53 TAD2. The ability of the full-length p53 TAD, or each of its subdomains, to function in yeast was previously shown to require the Spt7-Ada1-Gcn5-acetyltransferase (SAGA) chromatin-modifying complex, which is needed for the transcription of about 10% of yeast genes (7, 62) . Some of the components of the SAGA complex are encoded by nonessential genes (22). We therefore tested whether the SAGA complex was needed for transcriptional activation by the E1 NTR by performing transactivation assays in yeast strains lacking the Gcn5, Ada1, or Spt7 component of the SAGA complex. Gcn5 is the subunit that has acetyltransferase activity, while Ada1 and Spt7 are required for the structural integrity of the complex (reviewed in reference 3). The transactivation activity of both E1 and p53 was severely reduced in the Ada1 and Spt7 deletion strains, while the effect of deleting Gcn5 was more moderate ( Fig. 4C ; see Fig. S5A in the supplemental material), perhaps because the acetyltransferase activity of SAGA is not absolutely necessary for transactivation by these LexA fusion proteins. However, as detected by Western blotting, all LexA proteins were expressed at lower levels in these deletion strains to various extents (see Fig. S5B in the supplemental material). Nevertheless, the finding that transactivation by the E1 NTR is affected to an extent similar to that of p53 TAD2 by alteration of the SAGA complex provides further evidence that E1 AH is similar to p53 TAD2.
The E1 N-terminal region activates transcription weakly in human cervical carcinoma cells. Next we tested the ability of the HPV31 E1 NTR(1-83) to activate transcription in C33A cells when fused to the Gal4 DNA-binding domain. For comparison, we also measured in parallel the activities of the fulllength p53 TAD(1-73), p53 TAD2(40-73), and TAD of HPV31 E2 . Each Gal4 fusion was tested at three concentrations for its effect on expression of a firefly luciferase reporter gene under the control of five Gal4-binding sites. These studies revealed that the transactivation activity of the HPV31 E1 NTR was relatively weak, being approximately 10-fold lower than that of p53 TAD2, which was itself about 3-fold less potent than the complete p53 TAD (Fig. 5A ). These results are somewhat different than those obtained in yeast, where the transactivation activity of the HPV31 E1 NTR was 3-fold less than that of p53 TAD2 in strain EGY48 and 6.5-fold less in strain BY4741 ( Fig. 4 ; see Fig. S4 and S5 in the supplemental material). The activity of the HPV31 E1 NTR was about 5-fold lower than that of the HPV31 E2 TAD in C33A cells, demonstrating that although it is relatively weak, it is not dramatically different from that of a known viral transactivator in this Gal4 reporter gene assay. To test the generality of these findings, we measured the transactivation activities of the NTRs from HPV6, -11, -16, and -18 E1 and found that they were comparable to that of HPV31 (Fig. 5B) . Thus, the ability of the E1 NTR to weakly activate transcription in mammalian cells is conserved. Next, we tested the effects of mutations in the HPV31 E1 NTR. In several independent experiments, we found that its transactivation activity was reduced by approximately 40% by mutation of the three hydrophobic residues MFI (Fig. 5C ), a significant but smaller reduction than that observed in yeast. We also observed that mutation of T43 to alanine (T43A) had little to no effect, while mutation to glutamate (T43E) was always slightly inhibitory (Fig. 5C) . By Western blotting, we found that that the different Gal4-E1 NTR fusion proteins were always produced at very low levels in C33A cells, significantly less than those of p53 TAD2 and the HPV E2 TAD (Fig. 5A to C, right panels) . This was especially true for the NTRs of the two low-risk HPV types, HPV6 and HPV11, which were expressed at lower levels than those of the high-risk types (Fig. 5B) . It is thus possible that the lower expression of the E1 NTR contributes to its lower transactivation activity. From these studies, we conclude that the E1 NTR can activate transcription weakly in C33A cells. However, given this low level of transactivation, we surmised that the primary role of the E1 AH may be in viral DNA replication rather than in transcription per se (see Discussion). The experiments below were designed to address the role of the E1 AH in viral DNA replication.
Mutation of the E1 amphipathic helix reduces transient replication of HPV DNA. As the primary function of E1 is to replicate the viral genome, we investigated whether the E1 AH was required for HPV DNA replication. Specifically, we tested the effects of the MFI, T43A, and T43E mutations in HPV31 E1 on its ability to support transient DNA replication using our luciferase-based assay (19) . These experiments were performed with EYFP-HPV31 E1, which we showed previously is competent for DNA replication (18) . Each E1 mutant was tested at three different amounts (1.25, 2.5, and 5 ng of EYFP-E1 expression plasmid) in duplicate experiments, and luciferase activities were determined 72 h posttransfection. As can be seen in Fig. 6A , the T43A and T43E E1 mutations did not impair the ability of E1 to support transient DNA replication, indicating that phosphorylation of this residue is not required for this process. In contrast, the DNA replication activity of the MFI mutant was decreased by approximately 40 to 50%. All four E1 proteins were expressed to comparable levels, as determined by Western blotting (Fig. 6B) and by flow cytometry (see Fig. S6 in the supplemental material) .
Because the E1 AH is located between the shuttling module and the p80-binding site, we wanted to rule out the possibility that the reduced DNA replication activity of the MFI mutant was due to a defect in nuclear accumulation or a defect in interaction with p80. To do this, we first determined the cellular localization of the EYFP-E1 MFI mutant in the absence of E2. For sake of completeness, we also determined the localization of the two T43 mutants. All mutant E1 proteins accumulated in the nuclei of transfected cells, similar to wildtype (WT) E1 (Fig. 6C) , indicating that none of the mutations tested has a negative effect on the function of the nearby "shuttling module." We then investigated the interactions of these E1 mutants with p80 by GST pulldown experiments using purified GST-HPV31 E1(1-83) and endogenous p80 from a cell extract. Results presented in Fig. S7 in the supplemental material confirmed that all three mutant proteins were as competent as WT E1 in binding p80. Collectively, these results suggest that the E1 AH plays an important role in viral DNA replication that is independent of nuclear accumulation and p80 interaction.
DNA replication defect of the E1 MFI mutant as a function of time and E1 concentration. In order to ascertain the transient DNA replication defect of the E1 MFI mutant, we performed several additional mechanistic experiments. First, we investigated whether the replication defect of the MFI mutant would be affected by lengthening the duration of the transient DNA replication assay. To do so, we measured DNA replication catalyzed by the E1 MFI mutant, and by WT E1 as a control, every 24 h for a period of 5 days. Maximal signals were obtained after approximately 72 h for both proteins. Importantly, the signals obtained with the E1 MFI mutant remained 40 to 50% lower than those obtained with E1 WT at all time points tested (Fig. 7A) . Thus, regardless of the length of the assay, the E1 MFI mutant consistently showed a 40 to 50% reduction in transient DNA replication activity. Next, we tested whether the DNA replication defect of the E1 MFI mutant could be rescued by overexpression of the protein, as might be anticipated if this E1 mutant is slightly unstable or has a lower affinity for E2. To do so, we performed transient DNA on January 27, 2018 by guest http://jvi.asm.org/ replication assays using a wide concentration range of the E1 MFI expression vector and of the WT E1 vector as a control. As can be seen in Fig. 7B , the DNA replication signal obtained with WT E1 reached a plateau between 5 and 10 ng of expression plasmid. In contrast, the plateau obtained with the E1 MFI mutant was reached between 20 and 25 ng of expression vector and, importantly, was lower than that obtained with WT E1 by approximately 50%. Similar results were obtained with an E1 protein fused to a triple-Flag epitope (Fig. 7C) , rather than to EYFP, indicating that the replication defect imposed by the MFI mutation is independent of the tag fused to E1. The finding that the DNA replication defect of the E1 MFI mutant cannot be corrected by overexpression of the protein provides functional evidence that this mutation does not affect the stability of the protein and is entirely consistent with the results of the Western blot analysis (Fig. 6B) and flow cytometry analysis (see Fig. S6 in the supplemental material) described in the previous section. Importantly, the fact that the replication levels achieved with this mutant were always 40 to 50% lower than those obtained with WT E1 under all conditions tested suggests that the MFI mutation affects an intrinsic activity of E1 that is required for efficient replication of viral DNA. Mutation of the E1 amphipathic helix affects DNA replication at a step following assembly of the E1-E2-ori complex. In principle, the E1 MFI mutation could lower viral DNA replication by reducing the number of E1 molecules that can interact with E2 at the origin to initiate viral DNA replication and/or by affecting a subsequent step required for DNA synthesis. Thus, determining whether the MFI mutation affects the formation of the E1-E2-ori complex would provide an important clue as to when the E1 AH is required during DNA replication. In an initial attempt to determine whether the MFI mutation affects the initiation phase of DNA replication, we tested whether it had an effect on the interaction of E1 with E2 by coimmunoprecipitation. Specifically, C33A cells were cotransfected with an expression vector for EYFP-E1, either the wild-type, MFI mutant, or ATPase-deficient K463A protein, together with a plasmid encoding Flag-tagged E2. Twenty-four hours posttransfection, E1 was immunoprecipitated with an anti-GFP antibody, and the presence of E2 in the precipitate was probed by Western blotting using an anti-Flag antibody. Results shown in Fig. 8A demonstrate that E2 could be coimmunoprecipitated with wild-type E1 as well as with the two mutant proteins, suggesting that neither the MFI mutation nor the K463A mutation significantly affect the interaction of E1 with E2. To provide additional and more quantitative evidence that the MFI mutation does not affect the interaction of E1 with E2 in vivo, we made use of the ATPase-deficient K463A mutant E1. We previously showed that the corresponding mutation in HPV11 E1 (K484A) inhibits the ATPase activity of E1 but not its ability to bind cooperatively to the origin with E2 (54, 58) . Furthermore, we determined in the coimmunoprecipitation studies presented above that the HPV31 K463A E1 can still interact with E2. Thus, we rationalized that the HPV31 K463A E1 would have a dominant-negative effect on viral DNA replication and, furthermore, that this inhibitory effect would be reduced by the MFI mutation if it compromises the interaction of E1 with E2 at the origin. The results presented in Fig. 8B indicated that both the E1 K463A mutant and the E1 MFI/K463A double mutant could inhibit DNA replication catalyzed by WT E1 in a dominant-negative and dosedependent manner. Analysis of this inhibitory data by nonlinear regression confirmed that the E1 MFI/K463A double mutant was as good as E1 K463A at inhibiting viral DNA replication; both mutants were able to inhibit DNA replication by 50% (EC 50 ) when present at a ratio of approximately 1:1 relative to wild-type E1. If anything, the E1 MFI/K463A double mutant appeared to be slightly more potent than E1 K463A in this experiment, although this may simply reflect the fact that it was expressed at somewhat higher levels, as determined by Western blotting (data not shown). Thus, we conclude that the MFI mutation has little to no effect on the dominantnegative activity of E1 K463A, and by extension, we infer that the MFI mutation does not alter the ability of E1 to interact with E2. Consistent with the notion that the MFI mutation affects a replication activity of E1 other than its interaction with E2, we showed that the deleterious effect of the MFI mutation on transient DNA replication was additive, rather than synergistic, with that of the E39Q mutation in E2, which weakens the E1-E2 interaction (see Fig. S8 in the supplemental material). In summary, the results presented above provide in vivo evidence that the MFI mutation does not alter the interaction of E1 with E2. Next, we investigated whether the reduced replication activity of the E1 MFI mutant could be explained by a defect in origin binding by measuring its DNA-binding affinity in vitro using our previously described fluorescence polarization assay (20, 52) . First, we produced and purified from bacteria a polypeptide spanning amino acids 2 to 332 of HPV31 E1, either wild type or containing the MFI mutation (see Fig. S9A in the supplemental material). These polypeptides encompass the complete amino-terminal region and origin-binding domain (OBD) of E1. The affinities of these E1 fragments for a DNA probe containing two E1-binding sites (E1BS) (5Ј-ATACTT-3Ј) in an inverted orientation and separated by 3 bp were then measured. We previously determined that the E1 OBD can bind and dimerize efficiently on this combination of E1BS (19, 52) . A similar probe in which the two E1BS were mutated was used as a specificity control. As can be seen in Fig. 8C , both E1 fragments were able to bind specifically to the 2E1BS probe with comparable affinities. Thus, the MFI substitution does not impair the function of the OBD. Similar results were obtained with E1 fragments containing the T43A and T43E substitutions (see Fig. S9B in the supplemental material) .
Collectively, the results presented above indicate that the MFI mutation does not affect the interaction of E1 with either E2 or the origin. From these data, we infer that the E1 AH plays a role in viral DNA replication at a step following the assembly of the E1-E2-ori preinitiation complex.
DISCUSSION
The E1 N-terminal regulatory region contains a conserved amphipathic ␣-helix similar to p53 TAD2 and VP16C. Our deletion analysis of the HPV31 E1 N-terminal region (NTR) confirmed the importance of the p80-binding domain (aa 1 to 40) for transient HPV DNA replication and, importantly, identified the region located immediately next to it (aa 40 to 50) as also being required for this activity. In this study, we show that this region is highly conserved among E1 from several HPV types, lies within a predicted intrinsically disordered domain (IDD), and shows similarity to the p53 TAD2 and VP16C transactivation domains, which are also IDDs. IDDs are protein domains that have no intrinsic secondary structure in their free form but adopt a specific conformation when they bind to their target. This inherent flexibility allows them to interact with several different binding partners. It is therefore not surprising that IDDs are very common among eukaryotic proteins involved in regulatory and signaling processes, especially among transcription factors (reviewed in reference 21). The predicted E1 IDD is conserved in different HPV types ( Fig.  2A; see Fig. S3 in the supplemental material) and, as is typical of these unstructured domains, is of low sequence complexity, being largely devoid of hydrophobic amino acids (except for the MxxFI motif) and containing a high proportion of polar 1-83) does not possess any regular elements of secondary structure in the unbound form. Second, the presence of this predicted IDD region makes the E1 NTR migrate slower on SDS-polyacrylamide gels than predicted on the basis of its molecular weight (data not shown). Third, when expressed in E. coli, it is accessible to cleavage by bacterial proteases (see Fig. S9 in the supplemental material; also data not shown). Similarly, in mammalian cells, it is accessible to cleavage by caspases 3 and 7 (see Fig. S1 in the supplemental material), thus indicating that this region is solvent accessible.
The p53 TAD2 and VP16C IDDs fold into a 9-residue amphipathic ␣-helix (AH) upon binding to their target proteins such as the Tfb1/p62 subunit of TFIIH (12, 28, 30, 57) . Three key hydrophobic residues (⌽) located in a ⌽xx⌽⌽ motif on one face of this AH make direct contact with the target protein (Fig. 2C ). In agreement with the E1 IDD being structurally similar to p53 TAD2 and VP16C, our ITC and NMR chemical shift mapping studies revealed that a peptide spanning the conserved MxxFI hydrophobic motif of E1 binds the PH (pleckstrin homology) domain of Tfb1 with a comparable affinity and in a similar manner as p53 TAD2 and VP16C, indicating that it very likely folds into a similar AH. On the basis of these observations, we propose that the E1 NTR contains an IDD that folds into an AH to facilitate viral DNA replication.
The E1 NTR can activate transcription in yeast and, to a lesser extent, in mammalian cells. Consistent with the E1 NTR containing a region with similarity to p53 TAD2 and VP16C, we found that the E1 NTRs from five different HPV types (6, 11, 16, 18, 31) could activate transcription in yeast when fused to the LexA DNA-binding domain. This conserved transactivation activity of E1 was found to require the SAGA histone acetyltransferase complex, similar to what was shown for p53 TAD2 (7) and, importantly, to be dependent on the integrity of the MxxFI motif, underlying the role of the AH of E1 in this activity. When tested as a Gal4 fusion in mammalian cells, the E1 NTR was also capable of activating transcription, albeit to a lower extent than p53 TAD2, and mutation of the MxxFI motif reduced this activity by 40%. Thus, relative to p53 TAD2, the E1 AH appears to be a stronger activator in yeast than in mammalian cells. It was previously shown that the full-length HPV18 E1 protein can activate transcription weakly in mammalian cells when tethered to DNA by fusion to the E2 DNAbinding domain (10) . Our results are in complete agreement with this finding and point to the E1 NTR as being responsible for this activity.
At this time, it is unclear whether E1 functions as a transcription factor during the viral life cycle. The weak transactivation activity of E1 in mammalian cells (10; this study) suggests that it may not regulate transcription per se. One possibility could be that E1 needs to interact with one or more transcription factors to facilitate viral DNA replication. An equally plausible interpretation would be that the transcription activity of E1 simply reflects the fact that the NTR contains a region capable of folding into an AH. Indeed, several years ago, the research group of Ptashne reported that in yeast, artificial transactivation domains, selected from random pieces of DNA fused to the coding region of a heterologous DNAbinding domain, are acidic in nature and often predicted to contain AHs (35, 46) . Regardless of the exact significance of the E1 transactivation activity, our results indicate that the highly conserved AH is required for efficient replication of viral DNA, and we discuss below the possible roles that this AH may play in this process.
The E1 AH region is necessary for optimal viral DNA replication. As part of this study, we investigated the requirement for the E1 AH in viral DNA replication. We found that mutation of the MxxFI motif in the E1 AH reduced transient viral DNA replication by approximately 50%, irrespective of the duration of the assay or the level of expression of E1. Perhaps not surprisingly, this reduction in viral DNA replication brought about by the MFI mutation was of a similar magnitude as its effect in mammalian transactivation assays (40%; Fig.  5C ). Further mechanistic studies revealed that the E1 MFI mutant was able to accumulate in the nucleus, to interact with p80, and to bind to E2 and to the origin of replication as well as to wild-type E1. The finding that the E1 AH is not required for interaction with E2 is consistent with previous studies indicating that the C-terminal helicase domain of E1, rather than the NTR, mediates this interaction (36, 39, 51, 54, 61) . On the basis of these results, we propose that the E1 AH is implicated in a novel activity of E1 that is required for efficient replication of viral DNA at a step following assembly of the E1-E2-ori complex.
As part of this study, we also investigated the function of a highly conserved putative CK2 phosphorylation site, T43, located within the E1 AH. Mutation of T43 to alanine (to prevent its phosphorylation) or to glutamate (as a phosphomimetic) had little to no effect on the ability of HPV31 E1 to support transient DNA replication in C33A cells. Thus, the reason underlying the evolutionary conservation of this putative CK2 site remains unknown. It is also noteworthy that the sequence of the E1 AH overlaps the conserved caspase cleavage sites in E1, which were previously shown to be required for amplification of the viral genome in differentiated keratinocytes (37) . This prompted us to investigate whether one of the two T43 mutations or the MFI mutation that changes residues within the caspase sites (DxxDxxD and DMVDFID) had an effect on the susceptibility of E1 to caspase cleavage. Under our experimental conditions, none of the mutations had an effect (see Fig. S1 in the supplemental material). The fact that the MFI mutation has no effect on caspase cleavage but impairs DNA replication indicates that these two processes are distinct events. This notion is further supported by the findings that activated caspases are present only at very low levels in C33A cells (see Fig. S1 in the supplemental material) and that mutations of the caspase cleavage sites in E1 have little to no effect on DNA replication (Fig. S2) .
Potential functions of the E1 amphipathic helix in papillomavirus DNA replication. ⌽xx⌽⌽ motifs (where ⌽ represents a hydrophobic amino acid) present within ␣-helices are often involved in mediating protein-protein interactions. In addition to those in the p53 and VP16 TADs, other well-characterized examples include the LxxLL motif found in several transcrip-tional coactivators that bind to ligand-associated nuclear receptors (24, 31, 55) and the LxxLL motif present in many of the proteins that interact with the E6 protein of high-risk HPVs and bovine papillomavirus (BPV), such as E6AP whose LxxLL motif was shown to lie within an ␣-helix by NMR (4). Thus, the presence of the conserved MxxFI motif in the E1 AH raises the possibility that it also mediates a protein-protein interaction required for efficient replication of HPV DNA. A possible interaction partner may be E1 itself, for example if the AH region is required for proper assembly of a double hexamer at the origin. Alternatively, or in addition, this region of E1 could interact with cellular factors to promote viral DNA replication. Given that the papillomavirus genome is packaged into nucleosomes (16, 50) , E1 could interact with chromatin-remodeling complexes to facilitate progression of the replication fork. During the initiation phase of viral DNA replication, the transcription factor E2 relieves the inhibition exerted by nucleosomes at the origin. Interestingly, this antirepression mechanism can also be achieved by other transcription factors, including p53 and VP16, when tethered near the ori (33) . The E1 AH region could assume this function together with E2 or by itself, once E2 has been released from the initiation complex. The E1 AH could also promote replication of the HPV genome by interacting with the single-stranded DNA-binding protein RPA, a well-established target of p53 (1, 15) . Indeed, the TAD2 region of p53 has been reported to interact with the N-terminal part of RPA70 (RPA70N) with an affinity between 10 and 150 M (5). E1 was previously shown to interact with RPA, but the exact region of E1 responsible for this interaction has not yet been reported (23, 34). Interestingly, we have found in preliminary ITC experiments that the HPV11 E1 (44) (45) (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) (63) peptide can also bind to RPA70(1-120) with an affinity between 10 and 25 M (J. G. Omichinski, unpublished data). Remarkably, the crystal structure of the p53 TAD2-RPA70N complex (5), as well as the recent solution structure of TAD2 bound to the single-stranded DNA-binding protein PC4 (45) , have revealed that TAD2 binds within the DNA-binding domain of these proteins, acting as a single-stranded DNA mimic. By analogy, it is tempting to speculate that the E1 AH could also act as a single-stranded DNA mimic, perhaps to regulate the interaction of E1 with the single-stranded DNA (ssDNA) template generated during the unwinding process. Given that the E1 NTR requires the SAGA acetyltransferase complex for transactivation in yeast, one may also speculate that E1 interacts with related acetyltransferases in mammalian cells. Interestingly, the large T antigen helicase of polyomavirus has been shown to interact with p300/CBP-associated factor (PCAF) and GCN5 and to be acetylated by these enzymes to promote viral DNA replication (60) . Finally, the interaction of E1 with the PH domain of Tfb1/p62 reported herein suggests that E1 may also interact with TFIIH. As TFIIH is involved in both transcription and DNA nucleotide excision repair, it may play similar roles in the context of the viral episome. The E1 AH, and more generally the entire E1 IDD, could mediate interaction with several different cellular factors, the ones mentioned above representing a few possibilities. It is noteworthy that genes carried by small DNA tumor viruses often encode proteins with IDDs, as exemplified by the E1A protein of adenovirus (43) . The use of IDDs may thus represent an evolutionary solution for the need of these viruses to interact with a plethora of host factors to complete their life cycle despite the limited coding capacity of their genomes.
